Peptidomimetic Inhibitors of Herpes Simplex Virus Ribonucleotide Reductase with Improved in Vivo Antiviral Activity

Citations Over TimeTop 19% of 1996 papers

Abstract

We have been investigating the potential of a new class of antiviral compounds. These peptidomimetic derivatives prevent association of the two subunits of herpes simplex virus (HSV) ribonucleotide reductase (RR), an enzyme necessary for efficient replication of viral DNA. The compounds disclosed in this paper build on our previously published work. Structure-activity studies reveal beneficial modifications that result in improved antiviral potency in cell culture in a murine ocular model of HSV-induced keratitis. These modifications include a stereochemically defined (2,6-dimethylcyclohexyl)amino N-terminus, two ketomethylene amide bond isosteres, and a (1-ethylneopentyl)amino C-terminus. These three modifications led to the preparation of BILD 1351, our most potent antiherpetic agent containing a ureido N-terminus. Incorporation of the C-terminal modification into our inhibitor series based on a (phenylpropionyl)valine N-terminus provided BILD 1357, a significantly more potent antiviral compound than our previously published best compound, BILD 1263.

Related Papers

• → Ribonucleotide reductases — a group of enzymes with different metallosites and a similar reaction mechanism(1997)145 cited
• → Regulation of Ribonucleotide Reductase(1981)105 cited
• → A rapid and sensitive assay for quantifying the activity of both aerobic and anaerobic ribonucleotide reductases acting upon any or all substrates(2022)6 cited
• → Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N′-aminoguanidine derivatives(1985)26 cited
• → Regulation of Synthesis of Ribonucleotide Reductase and Relationship to DNA Replication in Various Systems(1996)20 cited